676128-63-5|RSV604|RSV604|MFCD28963952-范德生物科技公司

RSV604

NMR下载 COA and HPLC MSDS下载
names：
RSV604
CAS号：
676128-63-5
MDL Number： MFCD28963952
MF(分子式)： C22H17FN4O2 MW(分子量)： 388.39
EINECS:No data available Reaxys Number:No data available
Pubchem ID:5279172 Brand:BIOFOUNT

RSV604(676128-63-5)是一种新型的苯二氮卓类产品。RSV604是RSV病毒复制抑制剂，EC50值0.86uM，RSV核蛋白抑制剂。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000871-10mg	10mg	99.8%	¥ 1366.00	¥ 1366.00		2-3天	- +	¥ 0.00
YZM000871-5mg	5mg	99.8%	¥ 780.00	¥ 780.00		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	RSV604(676128-63-5);RSV 604;RSV-604
英文别名	RSV604,676128-63-5
CAS号	676128-63-5
SMILES	O=C1[C@@H](NC(NC2=C(F)C=CC=C2)=O)N=C(C3=CC=CC=C3)C4=CC=CC=C4N1
Inchi	InChI=1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,20H,(H,24,28)(H2,25,27,29)/t20-/m1/s1
InchiKey	MTPVBMVUENFFLL-HXUWFJFHSA-N
分子式 Formula	C22H17FN4O2
分子量 Molecular Weight	388.39
闪点 FP	301.6±30.1 °C
熔点 Melting point	No data available
沸点 Boiling point	575.0±50.0 °C at 760 mmHg
Polarizability极化度	42.6±0.5 10-24cm3
密度 Density	1.3±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±1.6 mmHg at 25°C
溶解度Solubility	生物体外In Vitro:DMSO溶解度≥ 195 mg/mL(502.07 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状	固体粉末,Power
储藏条件 Storage conditions	-20°C 3 years年 4°C 2 years年 /溶液中:-80°C 6 months月 -20°C 1 month月

RSV604(676128-63-5)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

RSV604(676128-63-5) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:RSV604(676128-63-5),RSV604试剂,RSV604抑制剂,RSV604的杂质,RSV604的纯度,RSV604的含量,RSV604的作用,RSV604的使用,RSV604的合成,RSV604的外观,RSV604的溶解度,RSV604的生产,RSV604的产量,RSV604的MSDS

产品说明	RSV604(676128-63-5)是一种新型的苯二氮卓类产品。RSV604是RSV病毒复制抑制剂，EC50值0.86uM，RSV核蛋白抑制剂。
Introduction	RSV604 (676128-63-5) is a new type of benzodiazepine products. RSV604 is an inhibitor of RSV virus replication, with an EC50 value of 0.86uM, RSV nucleoprotein inhibitor.
Application1
Application2
Application3

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults.(Current Infectious Disease Reports,2013)

Respiratory Syncytial Virus Disease: Prevention and Treatment.(Challenges and Opportunities for Respiratory Syncytial Virus Vaccines，2013）

Human Respiratory Syncytial Virus: An Introduction,(Human Respiratory Syncytial Virus,2016)

Antiviral activity of diarylheptanoid stereoisomers against respiratory syncytial virus in vitro and in vivo.(Journal of Natural Medicines,2013)

Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion: A Focus on Respiratory Syncytial Virus.(Protein-Protein Interactions,2012)

1.Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future.
Weisman LE Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):223-33.
Abstract:Respiratory syncytial virus (RSV) is a very important pathogen worldwide. It occurs and recurs naturally throughout life. Both short and long term morbidity, and mortality are particularly significant for infants, especially those infants with underlying conditions and risk factors. Current treatment strategies for these patients (e.g Ribavirin) are limited but several new interventions (e.g. RSV604, BTA9881, ALN-RSV01) are under investigation. Several preventive agents and strategies have been developed (e.g. RSV-IGIV, palivizumab) and others are in the pipeline (e.g. motavizumab) and under development (e,g, Medi-557). In this article, we review the RSV clinical condition with a focus on the highest risk populations. In addition we review prevention and treatment strategies of the past, present and future for these high-risk patients. This review should provide a single valuable source of information to clinicians and investigators.

2.1,4-Benzodiazepines as inhibitors of respiratory syncytial virus.
Carter MC;Alber DG;Baxter RC;Bithell SK;Budworth J;Chubb A;Cockerill GS;Dowdell VC;Henderson EA;Keegan SJ;Kelsey RD;Lockyer MJ;Stables JN;Wilson LJ;Powell KL J Med Chem. 2006 Apr 6;49(7):2311-9.
Abstract:Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as a serious threat to patient groups with poorly functioning immune systems. Our approach to finding a novel inhibitor of this virus was to screen a 20 000-member diverse library in a whole cell XTT assay. Parallel assays were carried out in the absence of virus in order to quantify any associated cell toxicity. This identified 100 compounds with IC(50)'s less than 50 muM. A-33903 (18), a 1,4-benzodiazepine analogue, was chosen as the starting point for lead optimization. This molecule was moderately active and demonstrated good pharmacokinetic properties. The most potent compounds identified from this work were A-58568 (47), A-58569 (44), and A-62066 (46), where modifications to the aromatic substitution enhanced potency, and A-58175 (42), where the amide linker was modified.

3.RSV604, a novel inhibitor of respiratory syncytial virus replication.
Chapman J;Abbott E;Alber DG;Baxter RC;Bithell SK;Henderson EA;Carter MC;Chambers P;Chubb A;Cockerill GS;Collins PL;Dowdell VC;Keegan SJ;Kelsey RD;Lockyer MJ;Luongo C;Najarro P;Pickles RJ;Simmonds M;Taylor D;Tyms S;Wilson LJ;Powell KL Antimicrob Agents Chemother. 2007 Sep;51(9):3346-53. Epub 2007 Jun 18.
Abstract:Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections worldwide, yet no effective vaccine or antiviral treatment is available. Here we report the discovery and initial development of RSV604, a novel benzodiazepine with submicromolar anti-RSV activity. It proved to be equipotent against all clinical isolates tested of both the A and B subtypes of the virus. The compound has a low rate of in vitro resistance development. Sequencing revealed that the resistant virus had mutations within the nucleocapsid protein. This is a novel mechanism of action for anti-RSV compounds. In a three-dimensional human airway epithelial cell model, RSV604 was able to pass from the basolateral side of the epithelium effectively to inhibit virus replication after mucosal inoculation. RSV604, which is currently in phase II clinical trials, represents the first in a new class of RSV inhibitors and may have significant potential for the effective treatment of RSV disease.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开